MENU

Will you profit from the emerging pathology services duopoly?

Most Australians are aware of the supermarket duopoly; we buy the vast majority of our groceries at either Woolworths (ASX: WOW) or Coles, which is owned by Wesfarmers (ASX: WES). The main reason for this is that enormous economies of scale have allowed the two big players to offer lower prices than smaller competitors. Furthermore, their importance as buyers means that they can squeeze suppliers, and operate a high volume, low margin business model.

One of the main reasons their business model allows for such low margins is that the big supermarkets operate with negative working capital. This means that they sell produce in their stores well before they actually pay suppliers. Although there are legitimate criticisms of the supermarket duopoly, the end result is, undeniably, lower prices.

A different kind of duopoly is emerging in the pathology industry. The main players are Primary Health Care (ASX: PRY) and Sonic Healthcare (ASX: SHL). However, unlike the supermarkets, healthy competition is not leading to lower costs for consumers, because the government (i.e. the taxpayer) picks up the tab.

Now you won’t hear me complaining about taxpayer funded healthcare – I am grateful every day to have been born in a country that looks after the sick and injured. However, it’s undeniable certain inefficiencies arise. For example, the government subsidy makes pathology quite a high margin business, which has led to intense competition in the sector (but unfortunately no falling prices for the taxpayer).

It appears that the landlords are gaining the most benefit. When the industry was deregulated in 2010, the number of pathology operators ballooned, but before long landlords began charging rents far in excess of the going commercial rate. This has led to a situation where smaller pathology providers are going out of business. Katherine McGrath, the CEO of the Australian Association of Pathology Practices describes the rents as “clearly excessive” and a “serious threat to the viability of pathology providers.”

Indeed, even the third-biggest provider, Healthscope, appears not to be faring very well. At the beginning of 2013, the private equity backed number-three player was closing centres and making staff redundant (whereas Sonic and Primary were both merrily continuing their expansion). Such is the competitive landscape that the ACCC keeps a close eye on the sector. The regulator knocked back Sonic’s attempt to buy Healthscope’s Queensland centres in 2012 (but allowed the acquisition of the Western Australian centres).

Foolish takeaway

Primary and Sonic are hardly confined to the pathology industry. The former owns all manner of medical practices, including a network of general practices. The latter specialises in diagnostic practices, such as radiology and pathology, and is an international company, owning businesses in Australia, New Zealand, the UK, the USA and continental Europe. Shares in both companies are up over 20% in the last 12 months, comfortably beating the market in 2013.

Looking to buy a market-beating company BEFORE the share price pops?

Readers can access our full analysis of 3 of our favourite long-term investments that you can buy right now. Each company pays an excellent dividend and boasts a strong underlying business. Check out our special FREE report "3 Stocks for the Great Dividend Boom" to discover the names of 3 of the best companies to buy now. Click here now to find out the names, stock symbols, and full research for three of our favourite income ideas, all completely free!

Motley Fool contributor Claude Walker (@claudedwalker) does not own shares in any of the companies mentioned in this article.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.